Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples

Experimental and Molecular Pathology

Volumn 92, Issue 3, 2012, Pages 275-280

  Didelot, Audrey ^a,b   Le Corre, Delphine ^a,b   Luscan, Armelle ^c   Cazes, Aurélie ^b,c   Pallier, Karine ^a   Emile, Jean François ^d   Laurent Puig, Pierre ^a,b,c   Blons, Hélène ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

BRAF; CAST PCR; EGFR; KRAS; Mutation; Targeted therapy

Indexed keywords

FORMALDEHYDE; PARAFFIN;

ACCURACY; ARTICLE; BRAF GENE; CALIBRATION; CLINICAL EXAMINATION; COMPETITIVE ALLELE SPECIFIC HYDROLYSIS PROBE POLYMERASE CHAIN REACTION; CONTROLLED STUDY; EGFR GENE; EMBEDDING; EXON; FORMALIN FIXED PARAFFIN EMBEDDED SAMPLE; GENE DELETION; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; KRAS GENE; MOLECULAR PROBE; MUTATIONAL ANALYSIS; PROCESS OPTIMIZATION; PROCESS TECHNOLOGY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TISSUE PREPARATION; TUMOR GENE;

CELL LINE, TUMOR; DNA PROBES; FORMALDEHYDE; GENOTYPE; GENOTYPING TECHNIQUES; HT29 CELLS; HUMANS; MUTATION; NEOPLASMS; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; TISSUE FIXATION;

EID: 84858961916     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.03.001     Document Type: Article

References (22)

1. Arcila M.E., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clinical Cancer Research 2011, 17:1169-1180.
2. Bustin S.A., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clinical Chemistry 2009, 55:611-622.
3. Cantwell-Dorris E.R., et al. BRAFV600E: implications for carcinogenesis and molecular therapy. Molecular Cancer Therapeutics 2011, 10:385-394.
4. Choi J.J., et al. PNA-mediated real-time PCR clamping for detection of EGFR mutations. Bulletin of the Korean Chemical Society 2010, 31:5.
5. Do H., et al. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008, 8:142.
6. Dufort S., et al. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. Journal of Experimental & Clinical Cancer Research 2011, 30:57.
7. Endo K., et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 2005, 50:375-384.
8. Kotoula V., et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One 2009, 4:e7746.
9. Laurent-Puig P., et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Journal of Clinical Oncology 2009, 27:5924-5930.
10. Li J., et al. Biotinylated probe isolation of targeted gene region improves detection of T790M epidermal growth factor receptor mutation via peptide nucleic acid-enriched real-time PCR. Clinical Chemistry 2011, 57:770-773.
11. Lievre A., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. Journal of Clinical Oncology 2008, 26:374-379.
12. Lin C.H., et al. Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer. Journal of Biomedical Science 2010, 17:37.
13. Lynch T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine 2004, 350:2129-2139.
14. Maheswaran S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. The New England Journal of Medicine 2008, 359:366-377.
15. Miyazawa H., et al. Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Science 2008, 99:595-600.
16. Mok T., et al. A small step towards personalized medicine for non-small cell lung cancer. Discovery Medicine 2009, 8:227-231.
17. Oxnard G.R., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clinical Cancer Research 2010, 17:1616-1622.
18. Pan Q., et al. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. Journal of Molecular Diagnostics 2005, 7:396-403.
19. Querings S., et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 2011, 6:e19601.
20. Sordella R., et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
21. Vultur A., et al. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clinical Cancer Research 2011, 17:1658-1663.
22. Wang J., et al. Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. Clinical Chemistry 2010, 56:623-632.